Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Tracheal Diseases 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Breast Cancer 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Combined Modality Therapy × Clear all
NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Servier

Phase 1/2 Completed
22 enrolled
Breast

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡